Minimally early morbidity in children with acute myeloid leukemia and hyperleukocytosis treated with prompt chemotherapy without leukapheresis  by Chen, Kuan-Hao et al.
Journal of the Formosan Medical Association (2014) 113, 833e838Available online at www.sciencedirect.com
ScienceDirect
journal homepage: www.jfma-onl ine.comORIGINAL ARTICLEMinimally early morbidity in children with
acute myeloid leukemia and
hyperleukocytosis treated with prompt
chemotherapy without leukapheresis
Kuan-Hao Chen a,b, Hsi-Che Liu b,c, Der-Cherng Liang b,c,
Jen-Yin Hou a,b, Ting-Huan Huang b, Ching-Yi Chang b,
Ting-Chi Yeh b,c,*a Mackay Medicine, Nursing and Management College, Taipei, Taiwan
b Division of Pediatric Hematology-Oncology, Department of Pediatrics, Mackay Memorial Hospital,
Taipei, Taiwan
c Mackay Medical College, New Taipei, TaiwanReceived 21 August 2013; received in revised form 9 December 2013; accepted 9 January 2014KEYWORDS
acute myeloid
leukemia;
chemotherapy;
children;
hyperleukocytosis;
leukapheresisConflicts of interest: The authors h
* Corresponding author. Division of
Section 2, Chung-Shan North Road, Ta
E-mail address: yeh@ms1.mmh.org
0929-6646/$ - see front matter Copyr
http://dx.doi.org/10.1016/j.jfma.201Background/Purpose: Patients with acute myeloid leukemia (AML) and hyperleukocytosis,
defined as an initial white blood cell (WBC) count of  100  109/L, are often treated with
leukapheresis. In this study, we have reported our experience of treating AML without leu-
kapheresis.
Methods: From November 1, 1995, to May 31, 2012, there were 74 children (18 years old)
with de novo AML other than acute promyelocytic leukemia. Seventeen patients had an
initial WBC count  100  109/L. Prompt chemotherapy was started within hours whereas
leukapheresis was not performed.
Results: The median age of the 17 patients with hyperleukocytosis was 7.4 years (range: 0
e16 years), and the median initial WBC count was 177  109/L (range: 117e635  109/L).
The median time between admission and initiation of chemotherapy was 4.5 hours (range:
2e72 hours) in patients with hyperleukocytosis, whereas it was 13 hours (range: 2e120
hours) in those without hyperleukocytosis. Seven patients (7/17, 41%) had one or more
early complications before or during the first 2 weeks of chemotherapy. Fifteen of the 16
patients who received prompt chemotherapy achieved complete remission (93.8%), compa-
rable with those without hyperleukocytosis (98.2%; p Z 0.33).ave no conflicts of interest relevant to this article.
Pediatric Hematology-Oncology, Department of Pediatrics, Mackay Memorial Hospital, Number 92,
ipei 10449, Taiwan.
.tw (T.-C. Yeh).
ight ª 2014, Elsevier Taiwan LLC & Formosan Medical Association. All rights reserved.
4.01.006
834 K.-H. Chen et al.Conclusion: Children with AML and hyperleukocytosis, treated with prompt chemotherapy
without leukapheresis, had minimal early morbidities.
Copyright ª 2014, Elsevier Taiwan LLC & Formosan Medical Association. All rights reserved.Introduction
Patients with acute myeloid leukemia (AML) and hyper-
leukocytosis, defined as an initial white blood cell (WBC)
count of 100  109/L, are at a high risk of early morbidity
and mortality.1 Early complications are attributed to leu-
kostasis, a phenomenon associated with sludging of
leukemic blasts in the microcirculation and adhesive in-
teractions with capillary endothelium, especially affecting
the brain and lung.2 Intracranial hemorrhage and respira-
tory distress are the main causes of early mortality.
Leukapheresis is often applied for patients with hyper-
leukocytosis to rapidly decrease their WBC count. Some
studies of adult patients have demonstrated that leuka-
pheresis decreases early mortality but does not impact
long-term outcome. Few studies have focused on the
management of pediatric AML with hyperleukocytosis.
Moreover, there is still no evidence that leukapheresis
should be the standard procedure for the initial treatment
of hyperleukocytosis. In pediatric patients, there are also
disadvantages of applying leukapheresis. The placement of
the large central venous catheter is more difficult to
perform in pediatric patients and may cause bleeding or
infections. Moreover, further thrombocytopenia and un-
stable blood pressure may occur during leukapheresis.
Therefore, we performed a prospective, single-center,
multiyear study to investigate the application of prompt
chemotherapy, instead of leukapheresis, as the initial
management for children with AML and hyperleukocytosis.
Materials and methods
Study design and patients
At Mackay Memorial Hospital (MMH), Taipei, Taiwan, there
were 74 patients under the age of 18 years with de novo AML
other than acute promyelocytic leukemia who were treated
with two consecutive protocols, namely, MMH-AML-96 and
Taiwan Pediatric Oncology Group (TPOG)-AML-97A, from
November 1, 1995, to May 31, 2012.3,4 Seventeen patients
hadan initialWBCcount 100109/L.Onepatient,whowas
deeply comatose due to severe multifocal cerebral hemor-
rhageatpresentation anddidnot receive chemotherapy,was
excluded from complete remission (CR) analysis.
Diagnosis
The diagnosis of AML and its subtypes was based on the
FrencheAmericaneBritish (FAB) classification.5e7 Immuno-
phenotyping and cytogenetic studies were performed in all
patients. Molecular genetic testing, including reverse
transcriptase-polymerase chain reaction assays and South-
ern blot analysis, was performed in all patients as previ-
ously described.8 In recent years, fluorescence in situhybridization was applied in the detection of mixed lineage
leukemia (MLL) gene rearrangement.
Treatment
At initial presentation, all patients immediately received
intravenous fluid hydration. Rasburicase (recombinant
urate oxidase) was used to treat hyperuricemia, if present.
Instead of leukapheresis, prompt induction chemotherapy
was given to all patients after a rapid initial diagnosis of
AML by leukemic cell morphology, cytochemical stain, and/
or immunophenotyping. The regimens of induction chemo-
therapy in both the MMH-AML-96 and TPOG-AML-97A pro-
tocol were identically Ara-C (100 mg/m2/day  7) plus
idarubicin (9 mg/m2/day  3). If CR was not achieved after
one cycle of induction therapy, another one cycle of in-
duction therapy with the same regimen was given. If CR
could not be achieved after two cycles, second-line treat-
ment including mitoxantrone (8 mg/m2/day  5) and eto-
poside (100 mg/m2/day  5) was given.
Initial outcomes
The CR was defined as less than 5% blasts in total nucleated
cells in bone marrow aspirate with a regeneration of normal
cell lines at the end of remission induction. Early compli-
cations and death were defined as events occurring before
or during the first 2 weeks of chemotherapy.9 Early com-
plications were further classified into neurological symp-
toms, respiratory distress, bleeding events, renal
insufficiency, and bacterial sepsis.
Statistical analysis
Comparisons of age, WBC count at diagnosis, and duration
from admission to initiation of treatment of the AML pa-
tients with and without hyperleukocytosis were performed
using the t test. Other characteristics of the patients based
on univariate analysis were performed by the c2 test. A p
value < 0.05 was taken to be significant.
Results
The characteristics of the patients with or without hyper-
leukocytosis are summarized in Table 1. The median age of
the patients with hyperleukocytosis was 7.4 years (range:
0e16 years), and the median initial WBC count was
177  109/L (range: 117e635  109/L). The most frequent
FAB subtypes were M4 and M5 (in 5 patients each), followed
by M1 and M2 (in 3 patients each), and M0 (1 patient). Four
patients had MLL gene rearrangements, one inv(16)/CBFb-
MYH11, one monosomy 7, one trisomy 8, one complex
karyotype, and nine normal karyotype. The abnormalities
of the MLL gene included t(9;11)/MLL-AF9 in two patients,
Table 1 Characteristics of the patients with or without hyperleukocytosis.
Characteristics Hyperleukocytosis
(n Z 17 patients)
Nonhyperleukocytosis
(n Z 57 patients)
p
Sex
Male 8 31 0.60
Female 9 26
Age (y)
Median 7.4 3.6 0.53
Range 0e16 0e17
WBC count at diagnosis (109/L)
Median 177 16.8 <0.001
Range 117e635 1e94
FAB classification
M0 1 3 0.12
M1 3 2
M2 3 18
M4 5 17
M5 5 7
M6 0 2
M7 0 8
Cytogenetics
MLL rearrangement 4 10 0.24
inv(16) 1 4
t(8;21) 0 10
Monosomy 7 1 0
Trisomy 8 1 0
Normal 9 27
Miscellaneous 1 6
Protocol
MMH-AML-96 2 5 0.65
TPOG-AML-97A 14 52
Time from admission to C/T (h)
Median 4.5 13 0.61
Range 2e72 2e120
WBC count at D14 (109/L)
Median 1.0 0.8 0.28
Range 0.4e2.2 0.2e1.8
Complete remission 15 (93.8%; n Z 16) 56 (98.2%; n Z 57) 0.33
Cycles to CR
1 10 44 0.003
2 2 12
3 3 0
Early death 1 (6.2%; n Z 16) 0 0.06
AML Z acute myeloid leukemia; C/T Z chemotherapy; CR Z complete remission; FAB Z FrencheAmericaneBritish; MMH Z Mackay
Memorial Hospital; MML Z mixed lineage leukemia; TPOG Z Taiwan Pediatric Oncology Group; WBC Z white blood cell.
Hyperleukocytosis without leukapheresis in childhood AML 835t(11;19)/MLL-ELL in one patient, and t(2;11)(q33;q23) in
another patient. The median time between admission and
initiation of chemotherapy was 4.5 hours (range: 2e72
hours) in the patients with hyperleukocytosis, and 13 hours
(range: 2e120 hours) in the patients without hyper-
leukocytosis. The median WBC count at Day 14 was
1.0  109/L (range: 0.4e2.2  109/L) in the patients with
hyperleukocytosis and 0.8  109/L (range: 0.2e1.8  109/L)
in the patients without hyperleukocytosis. One patient with
hyperleukocytosis and a stable clinical condition was hos-
pitalized on a Friday afternoon and received induction
chemotherapy 72 hours after admission.
The early complications in the patients with hyper-
leukocytosis are summarized in Table 2. Seven patients(7/17, 41%) had one or more early complications before or
during the first 2 weeks of induction chemotherapy,
including four with neurological symptoms, three with
respiratory distress, two with renal insufficiency, four with
bleeding events, and four with bacterial sepsis. One pa-
tient, who had an initial WBC count of 475  109/L and
received TPOG-AML-97A induction therapy within 24 hours
after admission, died on the 7th day from methicillin-
resistant coagulase-negative staphylococcal sepsis.
Fifteen of the 16 patients who received prompt chemo-
therapy achieved CR (93.8%). Ten patients achieved CR after
one cycle of induction therapy, two patients after two cycles,
and three patients after three cycles. The only patient with
monosomy 7, who achieved CR after three cycles of induction
Table 2 The initial outcomes and early complications of the patients with AML and hyperleukocytosis.
Patient Age (y) Sex FAB WBC at
Dx (109/L)
Early complications Time from
Ad to C/T (h)
CR ED
1 0.03 M M5 635 No 4 Yes No
2 0.81 F M4 475 TLS; RI: P/D  3 days;
MR-CONS sepsis
26 No Yes
3 9.02 F M1 437 Drowsy; RD; ICH,
subretinal hemorrhage;
TLS; Staphylococcus faecalis
sepsis
2 Yes No
4 7.91 F M4 302 Hallucination; RD; bilateral
vitreous hemorrhage; TLS;
RI: H/D twice
4 Yes No
5a 1.62 M M5 256 Coma; respiratory failure;
diffuse ICH
d d No
6 0.37 F M5 216 No 18 Yes No
7 5.37 M M1 203 No 5 Yes No
8 14.95 M M4 200 Rigidity; LGI bleeding 3 Yes No
9 15.61 M M2 177 Micrococcus luteus/Micrococcus
lylae sepsis
4 Yes No
10 12.19 F M0 171 No 72 Yes No
11 0.83 F M5 168 No 18 Yes No
12 2.92 M M4 135 No 20 Yes No
13 7.36 M M1 132 Klebsiella pneumoniae sepsis 4 Yes No
14 11.08 F M4 129 No 41 Yes No
15 10.27 F M2 118 No 4 Yes No
16 0.46 M M5 117 No 20 Yes No
17 11.17 F M2 117 No 2 Yes No
AdZ admission; AMLZ acute myeloid leukemia; C/TZ chemotherapy; CRZ complete remission; DxZ diagnosis; EDZ early death;
FZ female; FABZ FrencheAmericaneBritish; H/DZ hemodialysis; ICHZ intracranial hemorrhage; LGIZ lower gastrointestinal tract;
M Z male; MR-CONS Z methicillin-resistant coagulase-negative Staphylococci; P/D Z peritoneal dialysis; Pt Z patient;
RD Z respiratory distress; RI Z renal insufficiency; TLS Z tumor lysis syndrome; WBC Z white blood cell.
a Patient did not receive chemotherapy and was excluded from complete remission analysis.
836 K.-H. Chen et al.therapy, underwent allogeneic hematopoietic stem cell
transplantation using a matched sibling donor. One patient
with an initial WBC count of 436  109/L and initial pre-
sentations of intracranial hemorrhage, retinal hemorrhage,
and respiratory distress received intravenous hydration,
platelet transfusion, and twodoses of rasburicase (0.2mg/kg/
dose) to reduce serum uric acid from1370mmol/L to 0mmol/
L. Induction chemotherapy was initiated after 4 hours of
hospitalization. The neurological and respiratory symptoms
markedly improved in 1 week, and CR was achieved after one
cycle of induction therapy. For the baby with congenital AML
whohad thehighest initialWBCcount (635 109/L), induction
chemotherapy was initiated after 4 hours of hospitalization,
and CR without early complications was achieved after two
cycles of induction chemotherapy. The patients with hyper-
leukocytosis requiredmore induction cycles than the patients
without hyperleukocytosis to achieve CR. However, the CR
rates were similar (93.8% vs. 98.2%; pZ 0.33).Discussion
Hyperleukocytosis is a significant risk factor for early
morbidity and mortality in adult and pediatric patients with
AML.10 Leukostasis is the main pathogenesis accounting for
early complications and death. It was thought that withregard to leukostasis, a high leukocrit (fractional leukocyte
volume) led to an increase in blood viscosity, which then
caused an occlusion of microvessels.11,12 Accordingly, leu-
kostasis is more frequent in AML than in acute lympho-
blastic leukemia (ALL) because of the larger size of
myeloblasts than lymphoblasts. However, most recent
studies have demonstrated that interactions between
leukemic blasts and vascular endothelial cells may be the
key mechanism for leukostasis. Differences in adhesion
molecules expressed on myeloblast and lymphoblast sur-
faces may account for the higher incidence of leukostasis in
AML than in ALL.2,13
Inaba et al9 compared two groups with AML and hyper-
leukocytosis (before and after the AML-83 protocol) and
found that the incidence of early complications was similar,
but that early mortality rate was lower in the late period
group (2.8%) than in the early period group (22.9%). They
concluded that early mortality in hyperleukocytic AML pa-
tients could be decreased with advanced supportive care
and leukocytoreduction. Leukocytoreduction, which can be
achieved by leukapheresis or prompt induction chemo-
therapy, is now considered to be the initial management
choice for hyperleukocytic leukemia to prevent
complications.
The advantages of leukapheresis are its rapid cytore-
ductive effect and modulation of the cell cycle in bone
Hyperleukocytosis without leukapheresis in childhood AML 837marrow by increasing S-phase leukemic blasts, which can
theoretically increase the efficacy of cell cycle-directed
chemotherapeutic agents.14e16 The main disadvantage of
leukapheresis is the requirement of a large central venous
catheter, which is not always immediately available for
children and may increase the risk of infections. In addi-
tion, thrombocytopenia accompanied with WBC removal
and a rebound in blast count after leukapheresis are also
detrimental.17 Further thrombocytopenia and infections
may cause a delay in induction chemotherapy.
Although no randomized prospective studies regarding
the efficacy of leukapheresis have been published, several
retrospective studies have been reported. Thie´baut et al14
reported that leukapheresis performed in AML patients with
hyperleukocytosis (WBC count > 100  109/L) resulted in a
low early mortality rate (2 of 53). Porcu et al18 found that
the early mortality (within 1 week) rate was 29.1%, and
concluded that there was no correlation between the de-
gree of leukocytoreduction by leukapheresis and early
mortality. De Santis et al19 reported that seven of the 15
patients who had leukostasis and underwent leukapheresis
died within 1 week in spite of a significant reduction in WBC
count.
Some retrospective studies have compared hyper-
leukocytic AML patients who were treated with or without
leukapheresis. Giles et al20 compared two groups who had a
WBC count above 50  109/L and did (N Z 71) or did not
(N Z 75) undergo leukapheresis. The results showed that
leukapheresis reduced the 2-week mortality rate
(p Z 0.006) but showed no significant improvement in CR
and overall survival. Bug et al21 compared two hyper-
leukocytic (WBC count > 100  109/L) AML patient groups
who were treated with or without leukapheresis. The re-
sults showed a significantly lower risk of early death by Day
21 (pZ 0.015) with leukapheresis. Chang et al22 compared
two hyperleukocytic (WBC count > 100  109/L) AML pa-
tient groups with or without preinduction leukapheresis
according to the decision by the physician. The results
showed that leukapheresis did not significantly reduce early
mortality (p Z 0.367) or the incidence of intracranial
hemorrhage (p Z 0.349). However, they found that early
chemotherapy within 48 hours after hospitalization signifi-
cantly prevented early death (p Z 0.001).
Induction therapy is the mainstay of successful treat-
ment for acute leukemia. For patients with hyper-
leukocytosis, induction chemotherapy not only rapidly
reduces circulating WBC count, but also effectively de-
stroys the leukemic blasts in bone marrow. Therefore, in-
duction chemotherapy should be initiated as quickly as
possible. In addition, prompt induction chemotherapy does
not require an interventional procedure. Tumor lysis syn-
drome, which is the major concern after induction
chemotherapy in patients with hyperleukocytosis, can be
prevented by hydration, allopurinol, and rasburicase to
reduce serum uric acid levels,23 and correction of electro-
lyte imbalances or causes of reversible renal failure.24
In our study, the median duration for the initiation of
chemotherapy after admission was 4.5 hours. High CR and
low early mortality rates were achieved. However, the high
early complication rate (7/17) remains a challenge. More-
over, our patients with hyperleukocytosis required more
induction cycles than the patients withouthyperleukocytosis to achieve CR. Dutcher et al25 also
showed that hyperleukocytic AML patients had a lower CR
rate. This may be related to high tumor burden or distinct
entities of hyperleukocytic AML, which was associated with
fms-like tyrosine kinase 3-internal tandem duplication.26
However, the detailed pathophysiology is still uncertain.
This was an observational study, and the leukapheresis
comparison group was not included. Therefore, the data
were analyzed in a univariate fashion. Furthermore, the
number of patients included was small, and this limits the
significance of the statistical power.
In conclusion, prompt chemotherapy treatment for
children with AML and hyperleukocytosis can provide
satisfactory initial treatment results without leukapheresis.
Appropriate supportive care, including sufficient intrave-
nous hydration, treatment of tumor lysis syndrome,
correction of coagulopathy, and thrombocytopenia, should
be initiated immediately. Most importantly, the induction
chemotherapy should be started as soon as possible. Large
randomized prospective studies are necessary to compare
the initial outcomes of prompt chemotherapy alone versus
leukapheresis in pediatric patients with AML and
hyperleukocytosis.References
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